EUVIMEDEUVIMED entdecken
Crossref

The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies

Ryan P Nolan, David W Kang, Daniel C Maneval, Stephen P Knowles, Michael J LaBarre, Marie A Printz

Journal of Controlled Release · 2024-10 · 374 · 369-383

DOI: 10.1016/j.jconrel.2024.07.062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-10. Verfasst von Ryan P Nolan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Halozyme Therapeutics, Inc., San Diego, CA, USA. Hauptthemen laut MEDLINE: Hyaluronoglucosaminidase, Recombinant Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyaluronan (HA) is a glycosaminoglycan that forms a gel-like barrier in the subcutaneous (SC) space, limiting bulk fluid flow and the dispersion of SC-administered therapeutics. Recombinant human hyaluronidase PH20 (rHuPH20) facilitates the rapid delivery of co-administered therapeutics by depolymerizing HA in the SC space. Administration of rHuPH20 can induce the formation of anti-rHuPH20 antibodies, or anti-drug antibodies (ADAs), with the potential to bind endogenous PH20 hyaluronidase in the adult testes and epididymis. Using a variety of relevant animal models and multiple dose regimens of rHuPH20 across the full spectrum of animal development, we demonstrated that rHuPH20 administration resulted in the formation of ADAs. Although these ADAs can bind both the recombinant rHuPH20 enzyme and recombinant versions of animal model-specific hyaluronidases, they had no impact on fertility parameters (as measured by sperm concentration and motility, litter size, and litter viability) or fetal development. We present the result of our nonclinical studies in order of the developmental lifecycle, beginning with adults. Toxicology studies that extend beyond the standard package are also presented. These studies demonstrate the favorable safety profile of rHuPH20 and ADAs in nonclinical models. Additionally, we identified substantial safety margins for clinically relevant doses of rHuPH20.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyaluronoglucosaminidaseRecombinant ProteinsAnimalsFemaleMaleAntibodiesCell Adhesion MoleculesHyaluronic AcidDisease Models, Animal

Stichwörter der Autor:innen

Anti-drug antibodiesDevelopmentFertilityRecombinant human hyaluronidase PH20Subcutaneous

Substanzen

AntibodiesCell Adhesion MoleculesHyaluronic Acidhyaluronidase PH-20HyaluronoglucosaminidaseRecombinant Proteins

Autor:innen und Institutionen

  • Halozyme Therapeutics, Inc., San Diego, CA, USA.
  • Formerly with Halozyme Therapeutics, Inc., San Diego, CA, USA.
  • Halozyme Therapeutics, Inc., San Diego, CA, USA. Electronic address: mprintz@halozyme.com.

Zitieren

APA

Nolan, R. P., Kang, D. W., Maneval, D. C., Knowles, S. P., LaBarre, M. J., & Printz, M. A. (2024). The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies. Journal of Controlled Release, 374, 369-383. https://doi.org/10.1016/j.jconrel.2024.07.062

Vancouver

Nolan RP, Kang DW, Maneval DC, Knowles SP, LaBarre MJ, Printz MA. The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies. Journal of Controlled Release. 2024;374:369-383. doi:10.1016/j.jconrel.2024.07.062

BibTeX
@article{Nolan2024,
  author = {Nolan, Ryan P and Kang, David W and Maneval, Daniel C and Knowles, Stephen P and LaBarre, Michael J and Printz, Marie A},
  title = {The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies},
  journal = {Journal of Controlled Release},
  year = {2024},
  volume = {374},
  pages = {369--383},
  doi = {10.1016/j.jconrel.2024.07.062}
}
Kostenlos starten →